• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Oscar Health Inc.

    11/14/24 4:07:27 PM ET
    $OSCR
    Medical Specialities
    Health Care
    Get the next $OSCR alert in real time by email
    SC 13G/A 1 d904181dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1) *

     

     

    Oscar Health, Inc.

    (Name of Issuer)

    Class A Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

    687793109

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 687793109    13G    Page 2 of 5 Pages

     

     1.   

     Names of Reporting Persons

     

     Marc Stad

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     United States

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     22,224,667 (1)

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     22,224,667 (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     22,224,667 (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     9.9% (2)

    12.  

     Type of Reporting Person (See Instructions)

     

     IN, HC

     

    1

    Includes (i) 9,487,894 shares of Class A Common Stock of Oscar Health, Inc. (the “Issuer”) and (ii) 12,736,773 shares of Class A Common Stock issuable upon the conversion of the Issuer’s 7.25% Convertible Senior Notes due 2031 (the “2031 Convertible Senior Notes”) beneficially owned by the Reporting Person. Excludes 361,459 shares of Class A Common Stock into which the 2031 Convertible Notes may not currently be converted due to the Beneficial Ownership Limitation (as defined below). The 2031 Convertible Notes may not be converted to the extent that such conversion would result in the holder, or a person or group that includes such holder, beneficially owning in excess of 9.9% of the then outstanding shares of Class A Common Stock (the “Beneficial Ownership Limitation”).

    2 

    Based on (i) 211,754,816 shares of Class A Common Stock outstanding as of October 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 12,736,773 shares of Class A Common Stock issuable upon the conversion of 2031 Convertible Senior Notes.


    CUSIP No. 687793109    13G    Page 3 of 5 Pages

     

     1.   

     Names of Reporting Persons

     

     Dragoneer Investment Group, LLC

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

     Sole Voting Power

     

     0

       6.   

     Shared Voting Power

     

     22,224,667 (1)

       7.   

     Sole Dispositive Power

     

     0

       8.   

     Shared Dispositive Power

     

     22,224,667 (1)

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     22,224,667 (1)

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     9.9% (2)

    12.  

     Type of Reporting Person (See Instructions)

     

     IA, OO

     

    1 

    Includes (i) 9,487,894 shares of Class A Common Stock of Oscar Health, Inc. (the “Issuer”) and (ii) 12,736,773 shares of Class A Common Stock issuable upon the conversion of the 2031 Convertible Senior Notes beneficially owned by the Reporting Person. Excludes 361,459 shares of Class A Common Stock into which the 2031 Convertible Notes may not currently be converted due to the Beneficial Ownership Limitation.

    2 

    Based on (i) 211,754,816 shares of Class A Common Stock outstanding as of October 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on November 7, 2024 and (ii) 12,736,773 shares of Class A Common Stock issuable upon the conversion of 2031 Convertible Senior Notes.


    CUSIP No. 687793109    13G    Page 4 of 5 Pages

     

    AMENDMENT NO. 1 TO SCHEDULE 13G

    This Amendment No. 1 (“Amendment No. 1”) amends and supplements the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Ordinary Shares of the Issuer on February 14, 2024 (the “Schedule 13G”). Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Schedule 13G. Capitalized terms used but not defined in this Amendment No. 1 shall have the same meanings herein as are ascribed in the Schedule 13G.

    The following Items of the Schedule 13G are hereby amended and restated as follows:

     

    Item 4.

    Ownership

    (a) through (c)

    The information set forth in Rows (5) through (11) of the cover pages to this Schedule 13G is incorporated herein by reference for each Reporting Person.

    Dragoneer Investment Group, LLC (the “Dragoneer Adviser”) is a registered investment adviser under the Investment Advisers Act of 1940, as amended. As the managing member of Dragoneer Adviser, Cardinal DIG CC, LLC may also be deemed to share voting and dispositive power with respect to the Class A Common Stock. Marc Stad is the sole member of Cardinal DIG CC, LLC. By virtue of these relationships, each of the Reporting Persons may be deemed to share beneficial ownership of the Class A Common Stock of the Issue


    CUSIP No. 687793109    13G    Page 5 of 5 Pages

     

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 14, 2024

     

    /s/ Marc Stad
    Marc Stad
    DRAGONEER INVESTMENT GROUP, LLC
    By:   Cardinal DIG CC, LLC
    Its:   Managing Member
    By:   /s/ Pat Robertson
     

    Name: Pat Robertson

    Title: Chief Operating Officer

    Get the next $OSCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OSCR

    DatePrice TargetRatingAnalyst
    3/13/2025$20.00 → $16.00Overweight → Equal Weight
    Wells Fargo
    12/10/2024$12.00Underperform
    Jefferies
    11/6/2024$21.00 → $13.50Neutral → Underperform
    BofA Securities
    10/7/2024$23.00Neutral
    UBS
    6/26/2024$25.00Overweight
    Piper Sandler
    5/30/2024$28.00Outperform
    Robert W. Baird
    5/30/2024$25.00 → $21.00Buy → Neutral
    BofA Securities
    3/22/2024$20.00Outperform
    Raymond James
    More analyst ratings

    $OSCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oscar Health Inc.

      SC 13G/A - Oscar Health, Inc. (0001568651) (Subject)

      11/14/24 4:07:27 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Oscar Health Inc.

      SC 13G - Oscar Health, Inc. (0001568651) (Subject)

      11/14/24 1:28:35 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Oscar Health Inc.

      SC 13D/A - Oscar Health, Inc. (0001568651) (Subject)

      11/13/24 9:24:55 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Oscar Health, Inc. Announces Inducement Grants under Section 303A.08 of the NYSE Listed Company Manual

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), a leading healthcare technology company, announced that on January 22, 2024 the Compensation Committee of Oscar's Board of Directors approved the grant of employment inducement restricted stock unit awards covering an aggregate of 104,586 Class A shares of Oscar's common stock to 11 new non-executive employees of Oscar and its affiliates, to induce them to join Oscar and its affiliates. The awards generally vest quarterly over a one-year period following their vesting commencement date, subject to continued employment. The awards were granted under Oscar's 2022 Employment Inducement Award Plan as employment inducement awards pursuant to the New York

      1/26/24 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Welcomes Two Healthcare Veterans to its Executive Leadership Team

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built around a full stack technology platform, today announced the appointment of two seasoned healthcare executives to round out its leadership bench and further propel its vision to refactor healthcare. Kerry Sain has joined the company as the Executive Vice President of +Oscar, effective August 14, 2023, and Steven Kelmar will join as Executive Vice President and Chief of Staff to the CEO, effective September 21, 2023. In her role, Sain oversees the go-to-market strategy for the +Oscar business and will work closely with Mario Schlosser, President of Technology and Chief Technology Officer, to continue externa

      9/6/23 8:30:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. Appoints Dr. Sean Martin, MD as New Chief Medical Officer

      Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built on a full stack technology platform, today announced that Dr. Sean Martin, MD has been appointed to serve as the company's new Chief Medical Officer, effective immediately. Dr. Martin joined Oscar in 2016 and during his tenure has provided clinical leadership across a number of core clinical functions, including enterprise affordability, medical management, market performance, population health, and behavioral health. In his new role, he will be responsible for implementing Oscar's clinical capabilities and enhancing the quality of care and outcomes for its members. "Dr. Martin is an avid champion of the us

      3/15/23 8:30:00 AM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu

      5/7/25 6:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. 2025 First Quarter Earnings Conference Call

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 7, 2025 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentless

      4/9/25 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A

      With new backing from AIX Ventures, Peter Thiel, and healthcare and AI pioneers, Ataraxis AI is positioned to rapidly bring its first offering, Ataraxis Breast, to market Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE:OSCR), Ryan Fukushima, COO of Tempus, and others. Leading researchers from OpenAI and DeepMin

      3/5/25 2:13:00 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    SEC Filings

    See more
    • SEC Form 144 filed by Oscar Health Inc.

      144 - Oscar Health, Inc. (0001568651) (Subject)

      5/12/25 4:09:55 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Oscar Health Inc.

      10-Q - Oscar Health, Inc. (0001568651) (Filer)

      5/7/25 7:11:20 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Oscar Health, Inc. (0001568651) (Filer)

      5/7/25 6:24:47 AM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Financials

    Live finance-specific insights

    See more
    • Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu

      5/7/25 6:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health, Inc. 2025 First Quarter Earnings Conference Call

      Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 7, 2025 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentless

      4/9/25 8:00:00 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health Announces Fourth Quarter and Full Year 2024 Results; Introduces Full Year 2025 Outlook

      Reports Adjusted EBITDA and Net Income Profitability for the First Time in Company History For the year ended December 31, 2024: Total Revenue of $9.2 billion, a 56.5% increase year-over-year Medical Loss Ratio of 81.7%, a 10 bps increase year-over-year SG&A Expense Ratio of 19.1%, a 520 bps improvement year-over-year Net income attributable to Oscar of $25.4 million, or $0.10 of diluted earnings per share, a $296.2 million improvement year-over-year Adjusted EBITDA of $199.2 million, an improvement of $244.5 million year-over-year Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, today announced its financial results

      2/4/25 4:05:00 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thrive Partners Vii Growth Gp, Llc bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/22/24 4:33:02 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Co-Founder and Vice Chairman Kushner Joshua bought $3,185,681 worth of shares (188,395 units at $16.91) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/22/24 4:29:47 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • Director Thrive Partners Vii Growth Gp, Llc bought $5,444,343 worth of shares (344,522 units at $15.80) (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      11/18/24 5:02:12 PM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oscar Health downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Oscar Health from Overweight to Equal Weight and set a new price target of $16.00 from $20.00 previously

      3/13/25 8:18:37 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Jefferies initiated coverage on Oscar Health with a new price target

      Jefferies initiated coverage of Oscar Health with a rating of Underperform and set a new price target of $12.00

      12/10/24 7:59:30 AM ET
      $OSCR
      Medical Specialities
      Health Care
    • Oscar Health downgraded by BofA Securities with a new price target

      BofA Securities downgraded Oscar Health from Neutral to Underperform and set a new price target of $13.50 from $21.00 previously

      11/6/24 7:54:31 AM ET
      $OSCR
      Medical Specialities
      Health Care

    $OSCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Robinson Elbert O. Jr. sold $410,750 worth of shares (25,000 units at $16.43), decreasing direct ownership by 28% to 64,512 units (SEC Form 4)

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      5/14/25 4:20:39 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Plouffe David

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      4/14/25 4:17:56 PM ET
      $OSCR
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Gassen William

      4 - Oscar Health, Inc. (0001568651) (Issuer)

      4/14/25 4:17:43 PM ET
      $OSCR
      Medical Specialities
      Health Care